IGF-2 Peptide Therapy for Long-Lasting Blood Glucose Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diabetes, particularly type 1 and type 2 diabetes, involve inconvenient daily insulin injections with associated side effects and high costs, and there is a need for a more effective and long-term management of blood glucose levels.
Innovation Solution
Administration of insulin-like growth factor 2 (IGF-2) or variants thereof in specific daily doses to subjects, ranging from 65 μg/kg to 1626 μg/kg, to reduce glucose levels, increase insulin production, and enhance the number of functional beta cells, thereby reducing the need for daily insulin therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If daily insulin injections are used to treat diabetes, then blood glucose levels can be controlled, but the treatment requires ongoing daily therapy which is expensive and inconvenient for patients
Solution Approach 1:
The patent applies preliminary action by administering IGF-2 in advance to stimulate beta cell proliferation and insulin production before diabetes symptoms fully develop or to establish long-term insulin reserves. This preliminary stimulation of the pancreas allows for reduced or eliminated daily injections while maintaining blood glucose control, directly resolving the contradiction between reliable glucose control and daily injection convenience.
Solution Approach 2:
The patent enables self-service by using IGF-2 to stimulate the patient's own pancreas to produce sufficient insulin independently, eliminating the need for external daily insulin injections. The treatment activates the body's natural insulin production capacity, allowing the system to serve itself without ongoing external intervention, thus resolving the contradiction between glucose control reliability and injection convenience.
2Reliability
If daily insulin injections are used to treat diabetes, then blood glucose levels can be controlled, but the treatment causes side effects including low blood sugar, headache, hunger, weakness, sweating, tremors, irritability, trouble concentrating, rapid breathing, fast heartbeat, fainting, or seizure
Solution Approach 1:
The patent applies parameter changes by switching from exogenous insulin administration to IGF-2 administration, which changes the physiological parameters of insulin production and regulation. IGF-2 stimulates endogenous insulin production in a more controlled manner, maintaining blood glucose levels while avoiding the harmful side effects associated with external insulin therapy, thus resolving the contradiction between glucose control reliability and absence of side effects.
3Ease of operation
If IGF-2 is administered in high daily doses to maintain long-term blood glucose control, then the need for ongoing daily injections is eliminated, but the treatment cost and administration complexity increase
Solution Approach 1:
The patent applies preliminary action by using IGF-2 to stimulate and expand beta cell mass in advance, creating a reservoir of insulin-producing cells that can maintain glucose control without daily injections. This one-time or limited-duration preliminary stimulation eliminates the need for ongoing daily therapy, resolving the contradiction between ease of operation and treatment complexity by establishing long-term autonomy of the insulin production system.
Data Source
AI summary
The disclosure provides for peptides, fragments, compounds, compositions, and methods of use thereof for treating diabetes (e.g., type 1 diabetes, type 2 diabetes). In some aspects, methods comprise administering peptides, fragments, or a variant thereof to the subject for treating diabetes and diseases related to diabetes. In other aspects, compounds, compositions, and methods containing IGF-2 or variants thereof, IGF-2 peptides, and IGF-2 fragments are used for treating a disorder in a patient in need thereof, such as type 1 or type 2 diabetes.